Abstract
Purpose
Drug-resistant tuberculosis is a major public-health concern globally and can be difficult to manage clinically. Spinal tuberculosis is the most common manifestation of extrapulmonary tuberculosis. However, there have been few reports on the topic of drug-resistant spinal tuberculosis. The aim of this study was to investigate the clinical characteristics and drug susceptibility patterns and the outcomes of management with a combination of surgery and individualised chemotherapy, for drug-resistant spinal tuberculosis.
Methods
We retrospectively analysed 35 patients with drug-resistant tuberculous spondylitis. After surgery, individualised chemotherapy was tailored for each patient according to the drug-resistance profile and previous history of chemotherapy. The patients were followed up clinically and radiologically for an average period of 35.8 months.
Results
Among 35 drug-resistant spinal tuberculosis cases, 13 were retreatment cases. Twelve were multi-drug resistant tuberculosis (MDR-TB), and 23 were non-MDR-TB. The patients with MDR-TB and non-MDR-TB had undergone previous chemotherapy for an average of 14.50 ± 2.00 (0–60) months and 4.56 ± 1.54 (0–74) months, respectively. A total of 32 cases underwent open operations, and the other three had percutaneous drainage and local chemotherapy. Patients received individualised chemotherapy for an average of 23.6 months postoperatively. Local recurrence was observed in six patients. Thirty-three patients had been cured at the final follow-up, and the other two were still receiving chemotherapy.
Conclusions
Drug-resistant tuberculous spondylitis is mainly acquired through previous irregular chemotherapy and the spreading of drug-resistant strains. Management with a combination of surgery and individualised chemotherapy is feasible in the treatment of severe complications and the prevention of acquired drug resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10(9):621–629
World Health Organization (2010) Global tuberculosis control 2010. IOP Publishing PhysicsWeb. http://www.who.int/tb/publications/global_report/en/. Accessed July 2010
Pawar UM, Kundnani V, Agashe V, Nene A (2009) Multidrug-resistant tuberculosis of the spine-is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Spine (Phila Pa 1976) 34(22):806–810
Mukherjee JS, Rich ML, Socci AR, Joseph JK, Alcántara Virú F, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, Bayona J, Farmer P, Smith Fawzi MC, Seung KJ (2004) Programmes and principles in treatment of multi-drug resistant tuberculosis. Lancet 363(9407):474–481
Loddenkemper R, Sagebiel D, Brende A (2002) Strategies against multi-drug resistant tuberculosis. Eur Respir J 36(Suppl):66–77
Lee CK, Vessa Paul, Lee JK (1995) Chronic disabling low back pain syndrome caused by internal disc derangements: the results of disc excision and posterior lumbar interbody fusion. Spine 20(3):356–360 (Phila Pa 1976)
Jain AK (2010) Tuberculosis of the spine: a fresh look at an old disease. J Bone Joint Surg Br 92(B):905–913
Jassal M, Bishai WR (2009) Extensively drug-resistant tuberculosis. Lancet Infect Dis 9:19–30
World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. IOP Publishing PhysicsWeb. http://www.who.int/tb/publications/mdr_surveillance/en/. Accessed March 2010
Rüsch S, Gaby E, Casal M (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44(3):688–692
Yao C, Zhu T, Li Y, Zhang L, Zhang B, Huang J, Fu W (2010) Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray. Clin Microbiol Infect 16(11):1639–1643
Catharina C, Boehme PN (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363(11):1005–1015
Catharina C, Boehme MP, Nicol PN (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377(9776):1495–1505
Bazira J, Asiimwe BB, Joloba ML (2010) Use of the GenoType® MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clin Pathol 10(5)
Xu JZ (2006) The surgical indication and methods for spinal tuberculosis. Chin J Spine Spinal Cord 16(12):889–890
Dinc H, Ahmetoglu A, Baykal S, Sari A, Sayil O (2002) Image-guided percutaneous drainage of tuberculous iliopsoas and spondylodiskitic abscesses: midterm results. Radiology 225(2):353–358
Nagashima H, Yamane K, Nishi T, Nanjo Y, Teshima R (2010) Recent trends in spinal infections: retrospective analysis of patients treated during the past 50 years. Int Orthop 34(3):395–399
Acknowledgement
Appreciation is extended to Dr. Min Zhong, Dr. Yonglin Chen, Dr. Feng Wu and Chongqing Infecious Disease Medical Center, Chongqing, China for performing the drug susceptibility testing and data collection.
Author information
Authors and Affiliations
Corresponding author
Additional information
Litao Li and Zehua Zhang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Li, L., Zhang, Z., Luo, F. et al. Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy: a retrospective analysis of thirty-five patients. International Orthopaedics (SICOT) 36, 277–283 (2012). https://doi.org/10.1007/s00264-011-1398-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00264-011-1398-0